Amgenの第一四半期のnet incomeが、45%アップして$493M。CNNMoneyの記事はこちら。 これがどうしうて凄いかというと、Amgenという会社は基本的に1種類の発明だけでこれだけ儲けているのである。 Wall Street Journalによれば Amgen owes most of that growth to its drug Aranesp, which treats anemia, and Neulasta, which helps fight infections. Both drugs are second-generation versions of older products that brought in more than $250 million in the quarter. Amgen’s predecessor to Aranesp, an
![Amgenの大儲け-なぜバイオはすごいのか](https://cdn-ak-scissors.b.st-hatena.com/image/square/451186f07256698736cbbb2ceb4f4351b695701d/height=288;version=1;width=512/https%3A%2F%2Fchikawatanabe.com%2Fwp-content%2Fuploads%2F2018%2F12%2Fcropped-img_0084.jpg%3Fw%3D200)